GHRP-6 (5mg x 10) Ipamorelin (5mg x 10)

GHRP-6 (5mg x 10) Ipamorelin 5 mg x 10

1. Growth Hormone Releasing Peptide 6 (GHRP-6)
Growth hormone releasing peptides (GHRPs) are synthetic analogues of somatostatin, a naturally occurring neuropeptide. GHRPs mimic the effects of growth hormones by binding to specific receptors on the surface of cells. When bound to these receptors, they stimulate the release of growth hormones from the pituitary gland. These growth hormones then travel throughout the body stimulating cellular growth and reproduction.
2. GHRP-6
GHRP-6 is a synthetic analogue of somatostatin. Somatostatin is a naturally occurring neurohormone produced by the hypothalamus. It inhibits the secretion of growth hormone from the anterior lobe of the pituitary gland, thus inhibiting the production of insulin-like growth factor 1 (IGF-1). IGF-1 is a protein that stimulates cell division and growth. In addition, it promotes the synthesis of collagen and elastin, two structural components of connective tissue. Collagen is the primary constituent of bone, cartilage, tendons, ligaments, skin, blood vessels, and muscles. Elastin is the major constituent of elastic fibers, which provide structure and flexibility to many organs including lungs, intestines, and arteries.
3. Uses
GHRP-2 is commonly used as a diagnostic tool for measuring GH levels in humans. It is also used as a treatment for acromegaly, a condition characterized by excessive amounts of growth hormone. GHRP-2 is also used to treat children who have short stature due to low levels of growth hormone.
4. Dosage
The recommended dosage of GHRP-6 is 0.1 mg/kg per day. This dose should be administered subcutaneously once daily.

Ipamorelin

Description: Ipamorelin is a synthetic peptide agonist of Growth Hormone Releasing Factor (GHRF) receptor 1a. GHRF is a hypothalamic hormone that stimulates GH release from the pituitary gland. Ipamorelin mimics the action of GHRF and binds to its receptor.
The use of ipamorelin is indicated in patients with severe short stature due to idiopathic GHD who have failed to respond adequately to previous treatment with recombinant human GH.